Reduced recurrence of prostate cancer with novel autologous cancer vaccine (FK- PC101) post-prostatectomy: long-term results from a single-center phase 1/2 study
FK-PC101 demonstrated safety and potential clinical benefit in reducing prostate specific antigen (PSA) recurrence after RP in high-risk prostate cancer patients. These findings support further evaluation in a randomized phase 2 trial.
Authors
- Milton Berger (ORCID: https://orcid.org/0000-0001-6775-688X)
- Adam C. Stein (ORCID: https://orcid.org/0000-0002-5085-021X)
- Fernando Kreutz
- D. M. O. Freitas
Institutions
- Hospital de Clínicas de Porto Alegre (BR)
- Deoxi Biotecnologia (Brazil) (BR)
- Hospital Nossa Senhora da Conceição (BR)
- Celldex Therapeutics (United States) (US)
Publication Details
- Journal
- Future Science OA
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1080/20565623.2025.2550917
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00